Adverum Biotechnologies, Inc.(ADVM)Earnings, Financials & Key Ratios
ADVM•NASDAQ
Price updated Apr 24, 2026
AboutAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Show more
- Revenue$1M-72.2%
- EBITDA-$136M-9.9%
- Net Income-$131M-7.2%
- EPS (Diluted)-6.62-227.7%
- Gross Margin100%
- EBITDA Margin-13550.6%-295.6%
- Operating Margin-13915.9%-288.5%
- Net Margin-13092.7%-286.0%
- ROE-189.84%-93.3%
ADVM Key Insights
Adverum Biotechnologies, Inc. (ADVM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Strong 5Y sales CAGR of 32.0%
- ✓Share count reduced 65.9% through buybacks
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADVM Price & Volume
Adverum Biotechnologies, Inc. (ADVM) stock price & volume — 10-year historical chart
Loading chart...
ADVM Growth Metrics
Adverum Biotechnologies, Inc. (ADVM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.75%
5 Years31.95%
3 Years-48.91%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-88.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-109.27%
Return on Capital
10 Years-44.42%
5 Years-54.32%
3 Years-67.64%
Last Year-95.08%
ADVM Peer Comparison
Adverum Biotechnologies, Inc. (ADVM) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCGN | 419.77M | 1.24 | -5.39 | 8.83% | -16.05% | -1279.88% | ||
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 |
Compare ADVM vs Peers
Adverum Biotechnologies, Inc. (ADVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADVM Income Statement
Adverum Biotechnologies, Inc. (ADVM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.46M | 1.85M | 1.61M | 250K | 0 | 7.5M | 0 | 3.6M | 1M | 0 |
Revenue Growth % | -37.26% | 27.08% | -12.82% | -84.49% | -100% | - | -100% | - | -72.22% | -100% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 4.16M | 0 | 0 | 0 | 0 | 465K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -4.16M▲ 0% | 7.5M▲ 280.4% | 0▼ 100.0% | 3.6M▲ 0% | 1M▼ 72.2% | -465K▲ 0% |
Gross Margin % | - | - | - | - | - | 100% | - | 100% | 100% | - |
Gross Profit Growth % | -100% | - | - | - | - | 280.38% | -100% | - | -72.22% | - |
Operating Expenses | 116.74M | 60.7M | 79.69M | 68.8M | 113.79M | 153.62M | 157.13M | 132.54M | 140.16M | 206.85M |
OpEx % of Revenue | 8023.3% | 3282.64% | 4943.73% | 27518% | - | 2048.29% | - | 3681.72% | 14015.9% | - |
Selling, General & Admin | 24.36M | 20.86M | 24.56M | 28.38M | 44.64M | 64.44M | 57.86M | 55.06M | 63.12M | 79.44M |
SG&A % of Revenue | 1673.88% | 1128.02% | 1523.57% | 11350.4% | - | 859.21% | - | 1529.33% | 6311.8% | - |
Research & Development | 31.67M | 39.84M | 50.13M | 40.42M | 73.31M | 89.18M | 99.28M | 77.49M | 77.04M | 128.88M |
R&D % of Revenue | 2176.63% | 2154.62% | 3109.99% | 16167.6% | - | 1189.08% | - | 2152.39% | 7704.1% | - |
Other Operating Expenses | 60.71M | 0 | 5M | 0 | -4.16M | 0 | 0 | 0 | 0 | -1000K |
Operating Income | -115.28M▲ 0% | -58.85M▲ 49.0% | -78.08M▼ 32.7% | -68.55M▲ 12.2% | -117.95M▼ 72.1% | -146.12M▼ 23.9% | -157.13M▼ 7.5% | -128.94M▲ 17.9% | -139.16M▼ 7.9% | -207.32M▲ 0% |
Operating Margin % | -7923.3% | -3182.64% | -4843.73% | -27418% | - | -1948.29% | - | -3581.72% | -13915.9% | - |
Operating Income Growth % | -141.06% | 48.95% | -32.68% | 12.21% | -72.08% | -23.88% | -7.54% | 17.94% | -7.92% | - |
EBITDA | -113.68M | -56.75M | -76.33M | -66.97M | -113.79M | -141.48M | -150.61M | -123.3M | -135.51M | -204.82M |
EBITDA Margin % | -7813.13% | -3069.28% | -4735.17% | -26788.8% | - | -1886.36% | - | -3424.94% | -13550.6% | - |
EBITDA Growth % | -141.82% | 50.08% | -34.5% | 12.26% | -69.91% | -24.33% | -6.45% | 18.13% | -9.9% | -80.25% |
D&A (Non-Cash Add-back) | 1.6M | 2.1M | 1.75M | 1.57M | 4.16M | 4.64M | 6.53M | 5.64M | 3.65M | 2.49M |
EBIT | -54.57M | -58.85M | -73.08M | -68.55M | -116.39M | -146.12M | -157.13M | -128.94M | -139.16M | -207.94M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 762K | 2.7M | 4.2M | 4.06M | 1.56M | 582K | 2.67M | 5.75M | 8.23M | 2.92M |
Pretax Income | -114.52M▲ 0% | -56.15M▲ 51.0% | -73.88M▼ 31.6% | -64.49M▲ 12.7% | -116.39M▼ 80.5% | -145.54M▼ 25.0% | -154.46M▼ 6.1% | -123.19M▲ 20.2% | -130.93M▼ 6.3% | -204.39M▲ 0% |
Pretax Margin % | -7870.93% | -3036.61% | -4582.94% | -25794.4% | - | -1940.53% | - | -3422.06% | -13092.7% | - |
Income Tax | -775K | 0 | -1.25M | 0 | 1.11M | 0 | 74K | -1.08M | 0 | 0 |
Effective Tax Rate % | 0.68% | 0% | 1.69% | 0% | -0.96% | 0% | -0.05% | 0.88% | 0% | 0% |
Net Income | -113.75M▲ 0% | -56.15M▲ 50.6% | -72.63M▼ 29.4% | -64.49M▲ 11.2% | -117.51M▼ 82.2% | -145.54M▼ 23.9% | -154.54M▼ 6.2% | -122.12M▲ 21.0% | -130.93M▼ 7.2% | -204.39M▲ 0% |
Net Margin % | -7817.66% | -3036.61% | -4505.4% | -25794.4% | - | -1940.53% | - | -3392.11% | -13092.7% | - |
Net Income Growth % | -139.7% | 50.64% | -29.35% | 11.21% | -82.22% | -23.86% | -6.18% | 20.98% | -7.22% | -88.39% |
Net Income (Continuing) | -113.75M | -56.15M | -72.63M | -64.49M | -117.51M | -145.54M | -154.54M | -122.12M | -130.93M | -204.39M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.14▲ 0% | -1.29▲ 58.9% | -1.18▲ 8.5% | -0.87▲ 26.3% | -1.26▼ 44.8% | -1.48▼ 17.5% | -2.67▼ 80.4% | -2.02▲ 24.3% | -6.62▼ 227.7% | -8.70▲ 0% |
EPS Growth % | -70.65% | 58.92% | 8.53% | 26.27% | -44.83% | -17.46% | -80.41% | 24.34% | -227.72% | -109.27% |
EPS (Basic) | -3.14 | -1.29 | -1.18 | -0.87 | -1.26 | -1.48 | -2.67 | -2.02 | -6.62 | - |
Diluted Shares Outstanding | 36.25M | 43.66M | 61.38M | 73.8M | 93.31M | 98.36M | 57.98M | 57.98M | 19.78M | 23.49M |
Basic Shares Outstanding | 36.25M | 43.66M | 61.38M | 73.8M | 93.23M | 98.36M | 57.98M | 57.98M | 19.78M | 23.49M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ADVM Balance Sheet
Adverum Biotechnologies, Inc. (ADVM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 225.27M | 193.74M | 208.75M | 175.87M | 434.44M | 317.14M | 190.59M | 102.77M | 131.3M | 28.91M |
Cash & Short-Term Investments | 222.17M | 190.49M | 205.08M | 166.03M | 429.73M | 305.19M | 185.59M | 96.53M | 125.69M | 26.06M |
Cash Only | 222.17M | 70.52M | 154.95M | 65.9M | 62.42M | 34.2M | 68.43M | 75M | 60.65M | 26.06M |
Short-Term Investments | 0 | 119.97M | 50.13M | 100.14M | 367.31M | 270.99M | 117.16M | 21.53M | 65.04M | 0 |
Accounts Receivable | 886K | 0 | 0 | 0 | 0 | 5.71M | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 222.26 | - | - | - | - | 277.84 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 3.26M | 3.67M | 9.84M | 0 | 6.25M | 5.01M | 6.25M | 5.61M | 2.85M |
Total Non-Current Assets | 9.31M | 8.16M | 4.74M | 46.86M | 48.13M | 122.58M | 117.78M | 52.99M | 48.54M | 43.49M |
Property, Plant & Equipment | 4.17M | 3.02M | 3.59M | 45.85M | 47.1M | 119.06M | 113.86M | 49.79M | 45.22M | 39.49M |
Fixed Asset Turnover | 0.35x | 0.61x | 0.45x | 0.01x | - | 0.06x | - | 0.07x | 0.02x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 5M | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 999K | 999K | 0 | 3.27M | 2.5M | 0 | 0 | 1.98M |
Other Non-Current Assets | 140K | 140K | 156K | 11K | 1.03M | 250K | 1.41M | 3.21M | 3.32M | 2.02M |
Total Assets | 234.58M▲ 0% | 201.91M▼ 13.9% | 213.5M▲ 5.7% | 222.73M▲ 4.3% | 482.57M▲ 116.7% | 439.73M▼ 8.9% | 308.37M▼ 29.9% | 155.77M▼ 49.5% | 179.84M▲ 15.5% | 72.4M▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.01x | 0.00x | - | 0.02x | - | 0.02x | 0.01x | 0.00x |
Asset Growth % | -11.25% | -13.93% | 5.74% | 4.32% | 116.66% | -8.88% | -29.87% | -49.49% | 15.45% | -164.36% |
Total Current Liabilities | 9.9M | 10.67M | 10.72M | 19.41M | 20.87M | 21.32M | 32.25M | 19.98M | 22.9M | 44.75M |
Accounts Payable | 1.47M | 1.73M | 1.71M | 4.1M | 2.81M | 1.39M | 2.24M | 1.92M | 1.61M | 12.46M |
Days Payables Outstanding | - | - | - | - | 246.67 | - | - | - | - | 4.05K |
Short-Term Debt | 0 | 0 | 0 | 4.13M | 0 | 1.89M | 0 | 0 | 0 | 5.81M |
Deferred Revenue (Current) | 1.85M | 1.85M | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4M | 4.83M | 6.07M | 7.12M | 9.63M | 7.52M | 9.13M | 8.77M | 5.96M | 16.66M |
Current Ratio | 22.76x | 18.15x | 19.48x | 9.06x | 20.82x | 14.88x | 5.91x | 5.14x | 5.73x | 0.65x |
Quick Ratio | 22.76x | 18.15x | 19.48x | 9.06x | 20.82x | 14.88x | 5.91x | 5.14x | 5.73x | 0.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 9.09M | 7.2M | 1.61M | 28.36M | 27.35M | 102.22M | 94.61M | 68.56M | 86.23M | 83.31M |
Long-Term Debt | 0 | 0 | 0 | 100K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 28.21M | 26.23M | 101.11M | 93.56M | 68.56M | 86.04M | 339.97M |
Deferred Tax Liabilities | 1.25M | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 738K | 703K | 1.41M | 48K | 1.11M | 1.11M | 1.05M | 0 | 192K | 179K |
Total Liabilities | 18.98M | 17.88M | 12.33M | 47.77M | 48.22M | 123.54M | 126.85M | 88.55M | 109.13M | 128.05M |
Total Debt | 0 | 400K | 300K | 32.45M | 30.71M | 102.99M | 106.8M | 74.04M | 91.7M | 88.94M |
Net Debt | -222.17M | -70.12M | -154.65M | -33.45M | -31.72M | 68.8M | 38.37M | -959K | 31.05M | 62.88M |
Debt / Equity | - | 0.00x | 0.00x | 0.19x | 0.07x | 0.33x | 0.59x | 1.10x | 1.30x | -1.60x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.43x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.31x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 215.6M▲ 0% | 184.03M▼ 14.6% | 201.17M▲ 9.3% | 174.96M▼ 13.0% | 434.35M▲ 148.3% | 316.19M▼ 27.2% | 181.52M▼ 42.6% | 67.22M▼ 63.0% | 70.71M▲ 5.2% | -55.65M▲ 0% |
Equity Growth % | -14.64% | -14.64% | 9.31% | -13.03% | 148.26% | -27.2% | -42.59% | -62.97% | 5.19% | -330.96% |
Book Value per Share | 5.95 | 4.21 | 3.28 | 2.37 | 4.65 | 3.21 | 3.13 | 1.16 | 3.57 | -2.37 |
Total Shareholders' Equity | 215.6M | 184.03M | 201.17M | 174.96M | 434.35M | 316.19M | 181.52M | 67.22M | 70.71M | -55.65M |
Common Stock | 4K | 5K | 6K | 7K | 10K | 10K | 10K | 1K | 2K | 2K |
Retained Earnings | -197.91M | -254.06M | -320.54M | -385.03M | -502.54M | -648.08M | -802.61M | -936.02M | -1.07B | -1.21B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -7K | -963K | -799K | -725K | -261K | -714K | -1.53M | -473K | -407K | -440K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADVM Cash Flow Statement
Adverum Biotechnologies, Inc. (ADVM) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -38.37M | -45.42M | -53.96M | -49.17M | -79.29M | -107.83M | -108.09M | -90.9M | -92.46M | -137.9M |
Operating CF Margin % | -2636.84% | -2456.52% | -3347.64% | -19668% | - | -1437.75% | - | -2525.06% | -9246.2% | - |
Operating CF Growth % | -8.57% | -18.39% | -18.81% | 8.88% | -61.26% | -35.99% | -0.24% | 15.9% | -1.72% | -244.43% |
Net Income | -113.75M | -56.15M | -72.63M | -64.49M | -117.51M | -145.54M | -154.54M | -122.12M | -130.93M | -204.39M |
Depreciation & Amortization | 1.6M | 2.1M | 1.75M | 1.57M | 4.16M | 4.64M | 6.53M | 5.64M | 3.65M | 2.49M |
Stock-Based Compensation | 11.42M | 8.72M | 13.43M | 9.9M | 20.39M | 25.19M | 20.08M | 17.57M | 14.35M | 7.55M |
Deferred Taxes | 60.71M | 593K | -1.25M | -1.27M | 863K | 3.83M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 8K | 70K | 6.35M | 58K | 75K | -25K | -51K | 16.51M | 19.55M | 3.56M |
Working Capital Changes | 1.64M | -756K | -1.62M | 5.06M | 12.73M | 4.06M | 19.89M | -8.51M | 911K | 33.28M |
Change in Receivables | -437K | 886K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | -1.11M | -29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -111K | 333K | -67K | -650K | 1.58M | -1.61M | 845K | -369K | -262K | 10.39M |
Cash from Investing | 38.77M | -122.2M | 69.44M | -68.07M | -280.17M | 78.71M | 141.72M | 96.88M | -41.89M | 60.85M |
Capital Expenditures | -2.41M | -1.02M | -809K | -19.25M | -11.84M | -15.12M | -11.82M | -808K | -388K | -543K |
CapEx % of Revenue | 165.77% | 54.95% | 50.19% | 7698.8% | - | 201.64% | - | 22.44% | 38.8% | - |
Acquisitions | 3.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 38.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 556K | 16.75M | 69.95M | 28.19M | 355.99M | 2.4M | 607K | 69K | 120M | 10.26M |
Debt Issued (Net) | 0 | 0 | -175K | -112K | -61K | -240K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 607K | 489K | 1000K | 1.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 556K | 229K | -63K | 2.41M | 11.74M | 952K | 0 | -420K | 642K | 0 |
Net Change in Cash | 822K▲ 0% | -151.65M▼ 18549.0% | 85.43M▲ 156.3% | -89.05M▼ 204.2% | -3.47M▲ 96.1% | -26.73M▼ 669.5% | 34.24M▲ 228.1% | 6.04M▼ 82.4% | -14.35M▼ 337.5% | -66.79M▲ 0% |
Free Cash Flow | -40.78M▲ 0% | -46.44M▼ 13.9% | -54.77M▼ 18.0% | -68.42M▼ 24.9% | -91.14M▼ 33.2% | -122.95M▼ 34.9% | -119.91M▲ 2.5% | -91.71M▲ 23.5% | -92.85M▼ 1.2% | -138.44M▲ 0% |
FCF Margin % | -2802.61% | -2511.47% | -3397.83% | -27366.8% | - | -1639.39% | - | -2547.5% | -9285% | - |
FCF Growth % | -6.39% | -13.88% | -17.95% | -24.91% | -33.21% | -34.91% | 2.48% | 23.52% | -1.24% | -60.73% |
FCF per Share | -1.13 | -1.06 | -0.89 | -0.93 | -0.98 | -1.25 | -2.07 | -1.58 | -4.69 | -5.89 |
FCF Conversion (FCF/Net Income) | 0.34x | 0.81x | 0.74x | 0.76x | 0.67x | 0.74x | 0.70x | 0.74x | 0.71x | 0.68x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADVM Key Ratios
Adverum Biotechnologies, Inc. (ADVM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -48.59% | -28.1% | -37.71% | -34.29% | -38.57% | -38.78% | -62.1% | -98.19% | -189.84% | -3844.85% |
Return on Invested Capital (ROIC) | - | -82.24% | -73.01% | -54.68% | -32.51% | -27.83% | -38.97% | -67.59% | -124.23% | -297.56% |
Gross Margin | - | - | - | - | - | 100% | - | 100% | 100% | - |
Net Margin | -7817.66% | -3036.61% | -4505.4% | -25794.4% | - | -1940.53% | - | -3392.11% | -13092.7% | - |
Debt / Equity | - | 0.00x | 0.00x | 0.19x | 0.07x | 0.33x | 0.59x | 1.10x | 1.30x | -1.60x |
FCF Conversion | 0.34x | 0.81x | 0.74x | 0.76x | 0.67x | 0.74x | 0.70x | 0.74x | 0.71x | 0.68x |
Revenue Growth | -37.26% | 27.08% | -12.82% | -84.49% | -100% | - | -100% | - | -72.22% | -100% |
Related:ADVM Dividend History·ADVM Revenue History·ADVM Price History·ADVM P/E History·ADVM Financial Ratios·ADVM Institutional Holders
ADVM Frequently Asked Questions
Adverum Biotechnologies, Inc. (ADVM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adverum Biotechnologies, Inc. (ADVM) reported $1.0M in revenue for fiscal year 2024. This represents a 3233% increase from $0.0M in 2012.
Adverum Biotechnologies, Inc. (ADVM) saw revenue decline by 72.2% over the past year.
Adverum Biotechnologies, Inc. (ADVM) reported a net loss of $204.4M for fiscal year 2024.
Dividend & Returns
Adverum Biotechnologies, Inc. (ADVM) has a return on equity (ROE) of -189.8%. Negative ROE indicates the company is unprofitable.
Adverum Biotechnologies, Inc. (ADVM) had negative free cash flow of $138.4M in fiscal year 2024, likely due to heavy capital investments.